Ebola Survivors Have a Unique Retinal Scar

Article

Researchers from the University of Liverpool have conducted a study of Ebola survivors to determine if the virus has any specific effects on the back on the eye using an ultra widefield retinal camera.

These are composite scanning laser ophthalmoscope retinal images showing type 6 Ebola peripapillary or peripheral lesions, observed following the anatomic distribution of the ganglion cell axon (retinal nerve fiber layer), in a case-control study of ocular signs in Ebola virus disease survivors, Sierra Leone, 2016. A) Example 1, right eye. B) Illustration of the ganglion cell axon anatomic distribution. Courtesy of W.L.M. Alward. C) Example 2, right eye. Asterisks indicate curvilinear lesions distinct from the retinal vasculature. White arrowhead indicates retinal nerve fiber wedge defect. Courtesy of University of Liverpool
 
Researchers from the University of Liverpool have conducted a study of Ebola survivors to determine if the virus has any specific effects on the back on the eye using an ultra widefield retinal camera. To find out more about the broad-ranging symptoms of Post Ebola Syndrome (PES), a clinical research team led by Dr. Janet Scott and Dr. Calum Semple, from the University's Institute of Translational Medicine, assessed survivors discharged from the Ebola Treatment Unit at the 34th Regiment Military Hospital in Freetown, Sierra Leone.

Two years on from the Ebola outbreak in West Africa, and many Ebola survivors are still presenting with symptoms of post-Ebola syndrome (PES), including joint and muscle pains and psychiatric and neurological problems. 

Viruses, like Ebola, can stay hidden in our bodies by exploiting a vulnerability in our immune systems. This vulnerability is called "immune privilege," and comes from an old observation that foreign tissue transplanted into certain parts of the body don't elicit the usual immune response. This includes the brain, spinal cord, and eyes. Scientists believe this is because the brain, spinal cord, and eyes are simply too delicate and important to withstand the inflammation that's typical of an immune response.

An eye team led by Dr. Paul Steptoe, compared eye examinations of PES sufferers in Sierra Leone and the control population. A total of 82 Ebola survivors who had previously reported ocular symptoms and 105 unaffected controls from civilian and military personnel underwent ophthalmic examination, including widefield retinal imaging.

The results of the research, which has been published in the Emerging Infectious Diseases journal, shows that around 15 percent of Ebola survivors examined have a retinal scar that appears specific to the disease. 

Steptoe said, "The distribution of these retinal scars or lesions provides the first observational evidence that the virus enters the eye via the optic nerve to reach the retina in a similar way to West Nile Virus. Luckily, they appear to spare the central part of the eye so vision is preserved. Follow up studies are ongoing to assess for any potential recurrence of Ebola eye disease.

"Our study also provides preliminary evidence that in survivors with cataracts causing reduced vision but without evident active eye inflammation (uveitis), aqueous fluid analysis does not contain Ebola virus therefore enabling access to cataract surgery for survivors."

This work was supported by The Dowager Countess Eleanor Peel Trust, Bayer Global Ophthalmology Awards Program, Wellcome Trust ERAES Program and the NIHR Health Protection Research Unit in Emerging and Zoonotic Infections at the University of Liverpool.

The full paper, entitled 'Novel Retinal Lesion in Ebola Survivors, Sierra Leone, 2016', can be found here https://wwwnc.cdc.gov/eid/article/23/7/16-1608_article

Source: University of Liverpool
 

Related Videos
Baby visiting a pediatric facility  (Adobe Stock 448959249 by Rawpixel.com)
Antimicrobial Resistance (Adobe Stock unknown)
Anne Meneghetti, MD, speaking with Infection Control Today
Patient Safety: Infection Control Today's Trending Topic for March
Infection Control Today® (ICT®) talks with John Kimsey, vice president of processing optimization and customer success for Steris.
Picture at AORN’s International Surgical Conference & Expo 2024
Infection Control Today and Contagion are collaborating for Rare Disease Month.
Rare Disease Month: An Infection Control Today® and Contagion® collaboration.
Vaccine conspiracy theory vector illustration word cloud  (Adobe Stock 460719898 by Colored Lights)
Related Content